Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104193 | 0.85 | GRM5 (0.44) | GRM5PDE10AKDM4E | |
| SCHEMBL4203163 | 0.78 | GRM5 (0.47) | GRM5 | |
| SCHEMBL104787 | 0.77 | GRM5 (0.44) | GRM5 | |
| SCHEMBL103825 | 0.75 | GRM5 (0.44) | GRM5 | |
| Hydrochloric Acid SCHEMBL103140 | 0.73 | GRM5 (0.43) | GRM5 | |
| SCHEMBL103578 | 0.72 | GRM5 (0.42) | GRM5 | |
| SCHEMBL103114 | 0.71 | GRM5 (0.46) | GRM5 | |
| SCHEMBL103031 | 0.71 | MAPT (0.42) | GRM5KDM4E | |
| SCHEMBL398327 | 0.71 | EPHB4 (0.43) | GRM5ATMKDM4E | |
| SCHEMBL102760 | 0.71 | GRM5 (0.44) | GRM5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GRM5 1/4885ATM 3987/4885LMNA 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.